Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

Poland's Diagnostyka plans IPO on Warsaw bourse

Published by Global Banking and Finance Review

Posted on January 24, 2025

Featured image for article about Finance

GDANSK (Reuters) - Polish medical diagnostics firm Diagnostyka is planning an initial public offer (IPO) on the Warsaw Stock Exchange, the company said on Monday.

"The planned IPO is an important step to support the further development of the company and help us continue to strengthen our position in the market and increase shareholder value," CEO Jakub Swadzba said in a statement.

The planned offering will involve the sale of existing shares held by LX Beta S.à r.l., controlled by the MidEuropa III Management Limited, which currently holds 47.83% of Diagnostyka's shares.

Diagnostyka said it would not issue or offer new shares in connection with the IPO.

The offering will be addressed to retail and institutional investors in Poland and select international markets, with some 5% to 10% of the shares allocated to retail investors, it said.

The Diagnostyka Group, which started operations in 1998, said it was a market leader in Poland's medical diagnostics industry with more than 1,100 blood collection points, 156 laboratories and 19 imaging facilities.

It reported revenue of 1.6 billion zlotys ($382.9 million) in 2023 and 1.46 billion zlotys in the first nine months of 2024.

($1 = 4.1787 zlotys)

(Reporting by Marta Maciag; editing by Milla Nissi)